{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-017392","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.802054+00:00","generated_at":"2026-06-15T04:36:54.505960+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"COMPASS Pathways Q1 net loss $24.2M ($0.57/sh); Phase 3 psilocybin trials underway","bullets":["Net loss $24.2M ($0.57 loss per share) vs $21.2M ($0.50) in Q1 2022.","Cash $117.1M at March 31, 2023; raised additional $26.9M net via ATM in Q2.","Phase 3 pivotal trials (COMP 005, COMP 006) in TRD underway; top-line data expected summer 2024 and mid-2025.","CPT III code for psychedelic therapy support accepted by AMA, effective Jan 1, 2024.","FY 2023 net cash used in operating activities guidance $85M-$110M; Q2 guidance $22M-$30M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-017392","json":"https://secwatch.observer/filing/0001628280-23-017392.json","markdown":"https://secwatch.observer/filing/0001628280-23-017392.md","text":"https://secwatch.observer/filing/0001628280-23-017392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000162828023017392/0001628280-23-017392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000162828023017392/cmps-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:36:54.505960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1af0d4e64cbb47a7f71f0c60be37085bf6b73cd0","claim":"COMPASS Pathways plc reported the three months ended March 31, 2023 results: net income $24.2 million, EPS $0.57 loss per share.","evidence_excerpt":"Net loss for the three months ended 31 March 2023 was $24.2 million, or $0.57 loss per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816590/000162828023017392/0001628280-23-017392-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Net income","value":"$24.2 million"},{"label":"EPS","value":"$0.57 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}